• February 27, 2002

    More Imclone, More Food for Thought

    As you’ve no doubt heard, Imclone issued a press release this morning about their FDA meeting. It seems that if they can come up with more clinical data from Merck KGaA’s European trials, along with clarifying some of their own numbers, then the FDA has agreed to look at a resubmission. Bristol Meyers-Squibb has been… Read More
  • Who Dares, Wins?

    I’d like to take the time to sympathize with Elan Pharmaceuticals over what’s happened to their Alzheimer’s trial. They had the initiative (and the nerve) to pick up and run with an unusual discovery: that a protein that precipitates in the brains of Alzheimer’s patients, beta-amyloid, can be attacked by an immune response.… Read More
  • February 26, 2002

    A Certain Tension in the Air

    Well, today is Imclone day at the FDA (see Jan 31 and Feb. 6 postings.) All parties will be meeting to decide what the path forward is: reworking the existing data, supplementing it with whatever else the companies can dredge up, or new clinical trials. Analysts have raised the possibility of using some clinical data… Read More
  • New Drugs for HIV

    Megan McArdle points out the recent news (which has shown up in Tuesday’s NY Times and other outlets as well) about new HIV treatments with possibly fewer side effects. She asks if the same technique can be applied to other diseases, and I thought for the benefit of the non-pharma audience that I’d go into… Read More
  • February 25, 2002

  • February 24, 2002

    Toxicolottery

    I’ll continue to talk now and then about some topics that won’t necessarily be news to those inside the pharma industry. I see from my traffic stats that most of the hits are from outside it, although there are increasing numbers from both my own company and the competition. Thoughts of work prompt me to… Read More
  • February 22, 2002

    Cartesian Aging

    As I mentioned previously, I’ve been reading the letters of both Kingsley Amis and Philip Larkin. One thing you notice in any Collected Letters book (try Evelyn Waugh’s) is old age creeping up on the writers. It’s less noticable in Larkin’s case; his personality famously made him sound about 70 years old for decades. But… Read More
  • February 20, 2002

    Giordano Bruno

    I missed a chance yesterday to note an anniversary. Giordano Bruno was something of a crank, not normally the sort of person I’d be commemorating. But in his time, it didn’t take very much to be considered either of those, or worse, and we have to make allowances. He was headstrong. We can see now… Read More
  • February 18, 2002

    A Couple of Days Off

    I won’t be posting for another day or two; I’m taking tomorrow off from the Wonder Drug Factory and heading out with the family. My chemistry can get along without me just fine, and the people that report to me will most likely be even more productive without me around. Leaving the lab for a… Read More
  • February 14, 2002

Page 516 of 517« First...102030...513514515516517